Year archive

Calliditas Therapeutics — 2023 filings

All 32 regulatory filings released by Calliditas Therapeutics (CALTX) in 2023, sourced directly from the official regulator.

32 Filings

2023 Period

2023 filings (32)

Filing	Released	Lang
Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital Capital/Financing Update	2023-12-27	English
Calliditas refinansierar befintligt lån med en senior säkerställd lånefacilitet på 92 miljoner euro från Athyrium Capital Capital/Financing Update	2023-12-27	Swedish
Calliditas Therapeutics meddelar att FDA har gett fullständigt godkännande av TARPEYO®, den enda FDA-godkända behandlingen av IgA-nefropati som signifikant minskar förlusten av njurfunktionen Regulatory Filings	2023-12-20	Swedish
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function Regulatory Filings	2023-12-20	English
Calliditas erhåller Notice of Allowance avseende patentansökan i USA omfattande TARPEYO® Regulatory Filings	2023-12-11	Swedish
Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO® Regulatory Filings	2023-12-11	English
Calliditas announces additions to the management team Board/Management Information	2023-12-01	English
Calliditas utökar ledningsgruppen Board/Management Information	2023-12-01	Swedish
Interim / Quarterly Report 2023 Interim / Quarterly Report 9M 2023	2023-11-07	Swedish
Interim / Quarterly Report 2023 Interim / Quarterly Report 9M 2023	2023-11-07	English
Calliditas Therapeutics valberedning utsedd inför årsstämma 2024 AGM Information	2023-10-23	Swedish
Calliditas Therapeutics’ nomination committee composition for the AGM 2024 Board/Management Information	2023-10-23	English
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy Earnings Release FY 2023	2023-08-18	English
FDA beviljar prioriterad granskning för fullständigt godkännande av TARPEYO för behandling av IgA-nefropati Regulatory Filings	2023-08-18	Swedish
Interim / Quarterly Report 2023 Interim / Quarterly Report H2 2023	2023-08-17	Swedish
Interim / Quarterly Report 2023 Interim / Quarterly Report Q2 2023	2023-08-17	English
Kommuniké från årsstämman i Calliditas Therapeutics AB (publ) AGM Information	2023-05-30	Swedish
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) AGM Information	2023-05-30	English
Interim / Quarterly Report 2023 Interim / Quarterly Report Q1 2023	2023-05-16	Swedish
Interim / Quarterly Report 2023 Interim / Quarterly Report Q1 2023	2023-05-16	English
Alia Therapeutic appoints Board Director Board/Management Information	2023-05-09	English
Alia Therapeutics names Letizia Goretti as CEO Board/Management Information	2023-05-05	English
Kallelse till årsstämma i Calliditas Therapeutics AB (publ) AGM Information	2023-04-28	Swedish
Notice of annual general meeting of Calliditas Therapeutics AB (publ) AGM Information	2023-04-28	English
Annual Report 2022 Annual Report FY 2022	2023-04-26	Swedish
Alia Therapeutics Secures €4.4 Million Financing Regulatory Filings	2023-04-17	English
Calliditas presenterar att primärt effektmått framgångsrikt uppnåtts i NefIgArd Fas 3-studien som utvärderar Nefecon[®] i IgA-nefropati Earnings Release FY 2023	2023-03-12	Swedish
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy Earnings Release FY 2023	2023-03-12	English
Earnings Release 2022 Earnings Release Q4 2022	2023-02-23	Swedish
Interim / Quarterly Report 2022 Interim / Quarterly Report Q4 2022	2023-02-23	English
Number of shares and votes in Calliditas Therapeutics Declaration of Voting Results & Voting Rights Announcements	2023-01-31	English
Antal aktier och röster i Calliditas Therapeutics Declaration of Voting Results & Voting Rights Announcements	2023-01-31	Swedish